We hope to see you again soon!

You are now leaving Lundbeck UK's website (www.lundbeck.com/uk) for an external website. External links are provided as a resource to the viewer. Lundbeck UK are not responsible for the external website and its content.

UK-NOTPR-1010 | April 2022



At a Glance

Lundbeck in Brief

Lundbeck is a global pharmaceutical company specialising in developing innovative treatments for brain diseases. For more than 70 years, millions of people have been treated with our products and our development and distribution of pioneering therapies continues to make a difference to people worldwide.

Lundbeck in numbers


Lundbeck was founded by Hans Lundbeck in Copenhagen more than 100 years ago.


We are approximately 5,400 employees worldwide.


Our largest shareholder is the Lundbeck Foundation owning approximately 70%.


Our products are registered in more than 100 countries globally.

8 m

Our portfolio of products reaches more than 8 million people on a daily average.


Number of years that we have been building our neuroscience expertise.

Global presence

We are headquartered in Denmark and located in more than 50 countries around the world. We have production facilities in Denmark, France and Italy and research centres in Denmark and US.

We have employees in more than 50 countries and employ approximately 5,400 people across the value chain.


In 1999, Lundbeck’s shares were listed on Nasdaq Copenhagen. Our largest shareholder is the Lundbeck Foundation, which holds approximately 70% of the shares. The Foundation annually grants about DKK 500 million to support medical research and educational and communication activities.

More from Lundbeck

Our Science

Lundbeck has developed some of the most widely prescribed therapies for brain diseases.


Our products - the proud results of years of research.


Take your next career step with Lundbeck.

UK-NOTPR-1642 | September 2023